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Abstract: Highly active antiretroviral therapy (HAART) has greatly improved health parameters
of HIV infected individuals. However, there are several challenges associated with the chronic
nature of HAART administration. For populations in health transition, dual use of medicinal
plant extracts and conventional medicine poses a significant challenge. There is need to evaluate
interactions between commonly used medicinal plant extracts and antiretroviral drugs used against
HIV/AIDS. Efavirenz (EFV) and nevirapine (NVP) are the major components of HAART both
metabolized by CYP2B6, an enzyme that can potentially be inhibited or induced by compounds
found in medicinal plant extracts. The purpose of this study was to evaluate the effects of extracts
of selected commonly used medicinal plants on CYP2B6 enzyme activity. Recombinant human
CYP2B6 was used to evaluate inhibition, allowing the assessment of herb-drug interactions (HDI) of
medicinal plants Hyptis suaveolens, Myrothamnus flabellifolius, Launaea taraxacifolia, Boerhavia diffusa
and Newbouldia laevis. The potential of these medicinal extracts to cause HDI was ranked accordingly
for reversible inhibition and also classified as potential time-dependent inhibitor (TDI) candidates.
The most potent inhibitor for CYP2B6 was Hyptis suaveolens extract (IC50 = 19.09 ˘ 1.16 µg/mL),
followed by Myrothamnus flabellifolius extract (IC50 = 23.66 ˘ 4.86 µg/mL), Launaea taraxacifolia extract
(IC50 = 33.87 ˘ 1.54 µg/mL), and Boerhavia diffusa extract (IC50 = 34.93 ˘ 1.06 µg/mL).
Newbouldia laevis extract, however, exhibited weak inhibitory effects (IC50 = 100 ˘ 8.71 µg/mL) on
CYP2B6. Launaea taraxacifolia exhibited a TDI (3.17) effect on CYP2B6 and showed a high concentration
of known CYP450 inhibitory phenolic compounds, chlorogenic acid and caffeic acid. The implication
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for these observations is that drugs that are metabolized by CYP2B6 when co-administered with
these herbal medicines and when adequate amounts of the extracts reach the liver, there is a high
likelihood of standard doses affecting drug plasma concentrations which could lead to toxicity.
Keywords: herb-drug interactions; CYP450; time-dependent inhibition; reversible inhibition;
recombinant human CYPs
1. Introduction
It has been shown unequivocally that antiretroviral therapy (ART) reduces HIV/AIDS mortality
and prolongs life. However, attention has now shifted from reduction in mortality to improvement of
the quality of life for people taking ART [1,2]. Across the world, there are huge disparities in health
systems, thus, HIV/AIDS patients in different geographical regions receive different ART regimens
mostly due to the different cost of the more than 30 antiretroviral (ARV) drugs approved by the US FDA.
In resource constrained settings, the most commonly used ARV drugs include nevirapine (NVP) and
efavirenz (EFV) which form the backbone of highly active antiretroviral therapy (HAART) regimens;
thus, quite a number of patients use these two drugs during treatment [3,4]. Africa is a continent with a
high prevalence of HIV/AIDS making up approximately 67% of the world’s population of HIV infected
people [5]. Most ARV drugs used in Africa include EFV and NVP. EFV and NVP are non-nucleoside
reverse transcriptase I (NNRTIs) inhibitors which act by inhibiting the reverse transcriptase enzyme.
Both EFV and NVP are relatively affordable when compared to other ARV drugs [6]; hence, they are
widely used in many African countries. EFV and NVP are substrates of the CYP2B6 enzyme [7,8] and
plasma concentrations of these two ARVs are affected by changes in levels and activity of CYP2B6.
CYP3A4 also metabolizes these two drugs but its contribution appears to be marginal [9]. EFV and
NVP have been associated with a number of side effects including liver damage, nausea, vomiting,
fever, diarrhoea, dyslipidemia and headache [10].
CYP2B6 enzyme metabolizes many commonly used drugs including bupropion, propofol and
cyclophosphamide which should not be given together with EFV or NVP, to avoid drug-drug interactions.
Among populations in health transition, especially those in resource-constrained countries, patients often
make use of herbal medicinal plants in the management and treatment of several diseases in addition
to use of conventional drugs [11]. HIV infection is an epidemic in resource constrained countries,
particularly in sub-Sahara Africa; thus, it is inevitable that there is dual use of HAART and herbal
medicinal plants. Herbal medicine is much cheaper and readily available in most settings.
There is substantial evidence supporting the potential of medicinal plants in combating diseases,
especially in developing countries [12–15]. Although effective in the treatment of some diseases,
the mechanisms of action for most herbal medicines remain largely unknown. A wide range of
compounds (including phytochemicals) have been extracted from some of these medicinal plants so
it is not inconceivable to be able to predict possible effects of herbal medicines on enzymes, such as
CYP2B6, that metabolize commonly used drugs including EFV and NVP [16–18]. Some patients take
herbal medicines and conventional medicines at the same time in a bid to get better more quickly,
potentiating risk of herb–drug interaction (HDI) [19]. In spite of the wide use of herbal medications
among HIV/AIDs patients taking EFV or NVP-based HAART, data on their pharmacokinetic and
pharmacodynamics properties in humans remain lacking or scant [11,20]. Clinically significant
interaction of herbs with prescribed medications via drug metabolism may worsen the health condition
of patients if not detected earlier during treatment.
Cytochrome P450 enzymes (CYP450) are responsible for the metabolism of nearly 75% of phase
I-dependent metabolism of clinically used drugs [21]. Relative expression of CYP2B6 ranges from
2% to 10% of the total hepatic content [22–24] and contributes to a significant proportion of drug
metabolism [25]. Genetic polymorphism in CYP2B6 have been implicated in variations in the activity
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of the enzyme in metabolizing xenobiotics [26]. Inhibition of CYP2B6 by any drug, conventional
and/or herbal, is likely to present in a similar manner as portrayed by polymorphisms that result in
deficient enzyme activity. Thus, when herbal medicines are co-administered with ARV drugs, the
possibility of herb-ARV drug interaction might be clinically significant and may lead to significant
morbidity and mortality.
The purpose of this study was to evaluate the inhibition of CYP2B6 enzyme activity by selected
medicinal plant extracts used by HIV patients to treat HIV-associated opportunistic infections.
The medicinal plant extracts evaluated were extracted from Hyptis suaveolens, Boerhavia diffusa,
Newbouldia laevis, Launaea taraxacifolia and Myrothamnus flabellifolius.
2. Results
This study provides us with an opportunity to understand the effects of five medicinal
plants—Hyptis suaveolens, Boerhavia diffusa, Newbouldia laevis, Launaea taraxacifolia and
Myrothamnus flabellifolius—on CYP2B6 activity. Data presented here can help to increase awareness
among current and future patients of the potential effects of dual use of conventional drugs that are
metabolized xenobiotic metabolising enzymes such as CYP2B6 and the above herbal medicinal plants.
Our data shows that, indeed, for most of these herbal compounds, there is need for caution when
co-administering them with other medications.
2.1. Inhibition Screening and IC50 Determination
The potential of each medicinal plant extract to inhibit activity of recombinant human CYP2B6 is
presented in Figure 1 and Table 1. Four of the medicinal plant extracts inhibited CYP2B6 activity in a
concentration dependent manner. The potency of inhibition exhibited by the extracts was in the order
of Hyptis suaveolens (HS) > Myrothamnus flabellifolius (MF) > Boerhavia diffusa (BD) > Launaea taraxacifolia
(LT). Newbouldia laevis did not show any concentration dependent inhibitory effects.
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Figure 1. IC50 curve shift for Time Dependent Inhibition (TDI) determination. Hyptis suaveolens (HS), 
Boerhavia diffusa (BD), Myrothamnus flabellifolius (MF) and Launaea taraxacifolia (LT), at various 
concentrations were incubated with and without NADPH for 30 min. Percentage residual activity for 
Figure 1. IC50 curve shift for Time Dependent Inhibition (TDI) determination. Hyptis suaveolens (HS)
(a); Boerhavia diffusa (BD) (c); Myrothamnus flabellifolius (MF) (b) nd L unaea taraxacifolia (LT) (d), at
various concentrations were incubated with and without NADPH for 30 min. Percentage residual
activity for no pre-incubation (closed circles) and 30 min pre-incubation (closed squares) is shown.
Residual activity was calculated compared to control activity.
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The IC50 values for the medicinal plant extracts were determined as explained in the
materials and methods section. The medicinal plant extracts inhibited CYP2B6 in the order Hyptis
suaveolens (19.09 ˘ 1.16 µg/mL), Myrothamnus flabellifolius (23.66 ˘ 4.86 µg/mL), Launaea taraxacifolia
(33.87 ˘ 1.54 µg/mL) and Boerhavia diffusa (34.93 ˘ 1.06 µg/mL) (Table 1). Newbouldia laevis indicated
an IC50 of 100˘ 8.71 µg/mL, exhibiting very weak inhibitory effects on CYP2B6. Miconazole was used
as a standard diagnostic inhibitor of CYP2B6 whose observed IC50 value of 0.55µM is in agreement
with what has been reported elsewhere in literature [27].
Table 1. IC50 and IC50 fold shift due to incubation with or without Nicotinamide Adenine Dinucleotide
Phosphate (NADPH).
Inhibitor Conventional IC50(µg/mL) (Mean ˘ SEM)
IC50 (no Pre-Incubation
with NADPH) (µg/mL)
(Mean ˘ SEM)
IC50 (Pre-Incubation
with NADPH) (µg/mL)
(Mean ˘ SEM)
Fold Shift
(´IC50/+IC50)
Newbouldia laevi 100 ˘ 8.71 ND ND ND
Hyptis suaveolens 19.09 ˘ 1.16 10.60 ˘ 1.32 7.52 ˘ 1.20 1.40
Launeae taraxacifolia 33.87 ˘ 1.54 29.90 ˘ 1.32 9.47 ˘ 1.41 3.17
Boerhavia diffusa 34.93˘ 1.06 35.20 ˘ 2.86 30.70 ˘ 2.02 1.20
Myrothamnus
flabellifolious 23.66 ˘ 4.86 29.09 ˘ 1.74 24.11 ˘ 1.24 1.21
Miconazole 0.53 ˘ 0.14 0.63 ˘ 0.15 0.72 ˘ 0.20 0.88
2.2. Prediction of in Vivo Herb-Drug Interaction for IC50
The % yield and concentration per dose was calculated as shown in Table 2. Since the intestinal
absorption and plasma concentrations of each test compound are not known, and with the knowledge
that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was
calculated using the % yield to give the soluble extract available in the GI tract.
Table 2. Calculation of herbal medicine concentration in the gut.
Herbal Extracts % Yield Recommended HerbalDose (Single; mg)
Putative GIT
Concentration (µg/mL)
Estimated Bioavailable
Concentration (µg/mL)
Newbouldia laevis 14.66 200 800 117.28
Hyptis suaveolens 6.51 400 1600 104.16
Launaea taraxacifolia 10.40 200 800 83.3
Boerhavia diffusa 11.24 200 800 89.92
Myrothamnus
flabellifolius 10.80 200 800 86.4
Note: GIT, Gastrointestinal tract, estimated bioavailable concentration = (% yield ˆ putative GIT
concentration)/100.
Using this assumption, the putative GIT concentration was calculated as shown in Tables 2
and 3. The IC50 values obtained from the in vitro assay were then compared with the calculated
estimated bioavailable concentration and predictions made. Based on the IC50 values, it was predicted
that Hyptis suaveolens, Boerhavia diffusa, Myrothamnus flabellifolius and Launaea taraxacifolia were likely
to cause in vivo inhibition of CYP2B6 and with potential HDI (Table 3). It was observed that IC50
values for Hyptis suaveolens, Boerhavia diffusa, Myrothamnus flabellifolius and Launaea taraxacifolia were
approximately four times lower than the estimated bioavailable concentration and, therefore, adequate
amounts may enter the hepatic portal vein to interact with CYP2B6. However, it was observed that NL
had an IC50 value relatively similar to the estimated bioavailable concentration and, therefore, is not
expected to enter the hepatic portal vein to interact with CYP2B6.
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Table 3. In vivo prediction of HDI from in vitro for CYP2B6.
Herbal Extracts Inhibitor Concentration (µg/mL) IC50 (µg/mL) Risk of HDI in the Gut *
Newbouldia laevis 117.28 100 Unlikely
Hyptis suaveolens 104.16 20.33 Likely
Launaea taraxacifolia 83.20 33.87 Likely
Boerhavia diffusa 89.92 34.93 Likely
Myrothamnus flabellifolius 86.40 23.66 Likely
Note: HDI, herb-drug interaction, inhibitor concentration = estimated bioavailable concentration (µg/mL), *
the likelihood of a clinically relevant interaction when four of these herbal extracts are taken is based on the
assumption that the % yield serves as the bioavailable fraction which was used in estimating the bioavailable
concentration in the gut and also if there is complete absorption.
2.3. Time Dependent Inhibition (TDI) by IC50 Curve-Shift and Single Point NADPH Inhibition
Screening Evaluation
The IC50 curve shift assay was used to evaluate the TDI potencies of the various extracts. A
comparison was made between the IC50 values obtained with or without NADPH. The IC50-curve
shift showing the potency of the plant extracts to cause TDI is shown in Figure 1.
A fold decrease in IC50 was used to categorize a plant extract as a potential TDI. Extracts with
an IC50 ratio of ě1.5 were classified as positive TDIs as shown in Figure 2. Table 1 shows the shifted
IC50 obtained for the various extracts. Launaea taraxacifolia showed TDI potency with an IC50 fold
decrease of 3.17. However, Hyptis suaveolens, Boerhavia diffusa and Myrothamnus flabellifolius did not
exhibit a TDI effect on CYP2B6.
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Specific concentrations of the plant extracts were pre-incubated with or without NADPH and 
the percentage residual activity was compared (Figure 3). Medicinal plant extracts that were pre-
incubated with NADPH showed a reduction in the percentage activity of CYP2B6 compared to those 
without NADPH with a significant effect observed for the Launaea taraxacifolia extract indicating its 
time dependent inhibitory potency without the possibility of enzyme activity recovery. 
Figure 2. Ti e dependent inhibition (TDI) classification of medicinal plant extract incubation based on
IC50 curve shift.
Extracts of Hyptis suaveolens (HS), Boerhavia diffusa (BD), Myrothamnus flabellifolius (MF) and
Launaea taraxacifolia (LT) on recombinant CYP2B6. The bars represent ratio of IC50 values from the no
pre-incubation assays for the herbal extracts listed. Extracts that were >1.5 (dashed line) were classified
as TDI candidates. Data shown are the mean ˘ SEM (n = 2).
Specific concentrations of the plant extracts were pre-incubated with or without NADPH and the
percentage residual activity was compared (Figure 3). Medicinal plant extracts that were pre-incubated
with NADPH showed a reduction in the percentage activity of CYP2B6 compared to those without
NADPH with a significant effect observed for the Launaea taraxacifolia extract indicating its time
dependent inhibitory potency without the possibility of enzyme activity recovery.
Hyptis suaveolens (HS), Boerhavia diffusa (BD), Myrothamnus flabellifolius (MF) and
Launaea taraxacifolia (LT) on recombinant CYP2B6 after pre-incubation with or without NADPH
for 30 min. Percentage residual activities were plotted against respective fractions. Two-tailed
unpaired t-test was used to compare the percentage residual activity of each fraction with p < 0.05
considered significant.
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2.4. Relative Quantification of Selected Phenolic Compounds Using UPLC-MS
The relative quantification of phenolic compounds after UPLC-MS was performed using XCMS
data analysis software. Table 4 shows the relative quantification of the phenolic compounds analyzed
using MS detection expressed in mg¨kg´1 of original starting material used in the extraction,
whereas Figure 4 shows structures for some of the identified compounds. Hyptis suaveolens had
the highest content of chlorogenic acid (1665.33 ˘ 0.87 mg¨kg´1) followed by Launaea taraxacifolia
(1662.98 ˘ 2.10 mg¨kg´1). Launaea taraxacifolia however contained the highest content of caffeic acid
(998.59 ˘ 1.48 mg¨kg´1) followed by Hyptis suaveolens (100.00 ˘ 0.97 mg¨kg´1). Non-significant
traces of epicatechin and catechin were found in all the medicinal plant extracts except
Myrothamnus flabellifolius.
Table 4. Quantification of compounds identified in herbal extracts using MS detection.
Phenolic
Compound
Newbouldia
laevis
(Mean ˘ SEM)
Hyptis
suaveolens
(Mean ˘ SEM)
Launaea
taraxacifolia
(Mean ˘ SEM)
Boerhavia
diffusa
(Mean ˘ SEM)
Myrothamnus
flabellifolius
(Mean ˘ SEM)
Catechin Trace Trace Trace 1.40 ˘ 0.03 27.58 ˘ 0.10
p-Coumaric acid 7.54 ˘ 0.10 75.25 ˘ 0.10 751.41 ˘ 1.30 13.89 ˘ 0.10 39.13 ˘ 0.21
Caffeic acid 10.01˘ 0.01 100.00 ˘ 0.97 998.59 ˘ 1.48 10.59 ˘ 0.06 3.98 ˘ 0.01
Epicatechin Trace Trace Trace Trace 170.06 ˘ 0.39
Chlorogenic acid 166.77 ˘ 0.20 1665.33 ˘ 0.87 1662.98 ˘ 2.10 Trace 5.84 ˘ 0.10
Note: values are expressed as mg¨kg´1 for four biological replicates ˘ SD.
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3. Discussion
The use of medicinal plants for therapeutic purpose is a globally known phenomenon. When
adverse effects are experienced or cure fails, like in the case of HIV infection and cancer, limited
resources could be used to promote the use of herbal medicines. Thus, studies such as this one, which
seek to scientifically validate the safety of herbal medicines, are imperative. Herbal medicine is being
used for the treatment of a wide spectrum of disease conditions including cardiovascular and viral
disease, cancer and diabetes [29]. There is increasing evidence to also show that there is concomitant
use of herbal medicines with conventional medicines which leads to clinical complications resulting
from herb–drug interactions [11,19,30]. Studies on the drug interaction potential of herbal medicines,
especially those that have been in use for centuries, will help to create an awareness of the potential for
complications [31,32]. It is also imp rative that id ntification of he phy ochemical co stituen s in these
herbal medicines be performed to id ntify those lik ly to c use drug interactions. The advan age of
phytoche ical profiling is that similar drug interacting constituents could be identified in other related
herbs that are used for therapeutic purposes and that necessary mechanistic studies are performed on
them. Guidelines from the FDA relating to drug interaction and identification of compounds which
interact with drug metabolizing enzymes and transporters is of high value since these compounds
play a major role in affecting the pharmacokinetic and pharmacodynamics profiles of allopathic
medications [33].
In this study, five herbal medicines commonly taken to treat and manage the effects of HIV/AIDS
or its comorbidities by patients were evaluated for their ability to modulate activity of CYP2B6 in vitro
using recombinant human CYPs. Crude extracts of the herbal medicines were used because since
patients take these extracts in thei crude from, it became important that the effect of the crude form is
evaluat d. The method of extraction use for this study was also performed to mimic the indigenous
mode of extraction using water. The study showed that Launaea taraxacifolia Hyptis suaveolens,
Boerhavia diffusa and Myrothamnus flabellifolius extracts caused a concentration-dependent inhibition in
CYP2B6. The US FDA, EMA and pharmaceutical industries have published opinion documents and
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guidelines for the conduct of drug enzyme inhibition studies [34–36] which include reversible and
time dependent inhibition profiles of new chemical entities (NCE). A reversible inhibition profile was
thus conducted for the herbal extracts. It was observed that Hyptis suaveolens, Myrothamnus flabellifolius,
Launaea taraxacifolia and Boerhavia diffusa had a reversible inhibitory effect on the activity of CYP2B6.
Newbouldia laevis, however, did not show any significant inhibitory effects on the activity of CYP2B6
based on the concentration range assessed.
Based on the recommended dosage taken by patients, the GIT concentration was calculated and
% yield used to estimate the bioavailable concentration (Table 2) and the possibility of causing HDI
in vivo determined. Here, a comparison was made between the amount of extract in the gut and
the IC50 concentrations obtained. If the amount in the gut is at least two-fold (2ˆ) or more higher
than the IC50, then it is expected that adequate amounts of the extract will reach hepatic CYP2B6 to
cause clinically significant HDI [37]. It was observed that Hyptis suaveolens, Myrothamnus flabellifolius,
Launaea taraxacifolia and Boerhavia diffusa were likely to cause HDI in the gut (Table 3). Newbouldia laevis,
however, seems unlikely to cause an HDI in the gut (Table 3). Thus, patients taking Hyptis suaveolens,
Myrothamnus flabellifolius, Launaea taraxacifolia and Boerhavia diffusa would need to exercise caution as
these herbs are likely to inhibit CYP2B6 and could render drugs that are CYP2B6 substrates—which
include efavirenz and nevirapine—toxic.
According to US FDA, EMA and pharmaceutical industries guidelines on the conduct of drug
enzyme inhibition studies [34,36,38], NCE that show significant reversible inhibition should also
be assessed for time dependent inhibitory (TDI) effects. The IC50 shift approach is one of the
recommended methods for TDI assessment [39,40]. A significant shift towards the left in the inhibition
curves after pre-incubation shows potency for TDI. The method was validated with miconazole
which has not been known to show any TDI effects. According to Berry and Zhao [39], a fold
shift or IC50-shift decrease of ě1.5 is significant for a NCE to be called a TDI compound. In this
study, therefore, this criterion was used to classify the herbal extracts as potential TDI candidates.
Launaea taraxacifolia showed an IC50-shift decrease of 3.17 and was thus classified to be a potential TDI
candidate. Hyptis suaveolens, Myrothamnus flabellifolius and Boerhavia diffusa showed fold decreases
of 1.40, 1.21 and 1.20, respectively. The effect of NCE that causes TDI is that even if the usage of
the compound is discontinued, there is permanent destruction of enzyme which requires de novo
synthesis of the enzyme of interest. Potential TDI compounds asserts inhibitory effects through
formation of more inhibitory metabolites or the irreversible inactivation of enzymes by metabolic
products that form haem or protein adducts [41]. Launaea taraxacifolia thus having been classified as a
potential TDI candidate in this study demonstrates potential in inhibiting CYP2B6. Hyptis suaveolens,
Myrothamnus flabellifolius and Boerhavia diffusa exhibited a non-TDI effect suggesting the potential of
these three herbs interacting reversibly with CYP2B6.
Launaea taraxacifolia has been used for centuries in West African countries such as Ghana
and Nigeria as a vegetable and also for managing dyslipidemia and liver diseases [42] which
are complications of HIV/AIDS, its comorbidities [43–46] and HAART [10,47–49]. Patients on
HAART regimens containing EFV and NVP are likely to experience adverse drug effects from
Launaea taraxacifolia when used together. In resource-limited settings, Launaea taraxacifolia is a
commonly used vegetable; thus, herb–drug interactions are highly likely to be reported.
Although the study analyzed effects of the crude herbal extracts as taken by patients and did
not evaluate the effects of the individual phytochemical constituents or fractions, UPLC-MS was used
to quantify some phenolic compounds known for their therapeutic effects and some that have been
implicated in CYP inhibition. Quantification of catechin, p-coumaric acid, caffeic acid, epicatechin
and chlorogenic acid was performed with known standards and analyzed using XCMS data analysis
software. Extract from Launaea taraxacifolia showed high content of chlorogenic acid (1662.98 mg¨ kg´1)
and caffeic acid (998.59 mg¨kg´1) (Table 4) with though these were also present in Hyptis suaveolens,
Myrothamnus flabellifolius and Boerhavia diffusa also contained varying amounts. Caffeic acid [50] and
chlorogenic acid [51,52] have been implicated in the inhibition of CYP450 activity in vitro. It is therefore
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postulated that the inhibitory effects observed on CYP2B6 in the study could be via the effects of
these phenolic compounds. Other phenolic compounds—for example catechin, epicatechin [53] and
p-coumaric acid [54], known for their antioxidant and anti-inflammatory effects—were also found in
the extracts which also explains some of their therapeutic uses.
4. Materials and Methods
4.1. Chemicals and Reagents
Miconazole nitrate was purchased from Sigma-Aldrich (St. Louis, MO, USA). Black costar 96
well plates were obtained from Thermo Fischer Scientific (Pittsburgh, PA, USA). Vivid® CYP450
Blue Screening Kit and Vivid® Substrate, 7-benzyl-oxymethyloxy-3-cyanocoumarin, (BOMCC) were
purchased from Life Technologies, (Grand Island, NY, USA). Standard for epicatechin, catechin,
chlorogenic acid, caffeic acid and p-coumaric acid for identification of constituents of herbal extracts
were purchased from Chromadex (Wesel, Germany). Purified water (double-distilled and deionized)
was obtained from Millipore (Bedford, MA, USA).
4.2. Plant Material
The following plants Hyptis suaveolens (UCC/BS/687), Boerhavia diffusa (UCC/BS/688),
Newbouldia laevis (UCC/BS/689) and Launaea taraxacifolia (UCC/BS/690), Table 5, used in the study
were obtained and authenticated by botanists from the University of Cape Coast and samples were
kept in the herbarium in the department of Biological sciences with voucher numbers as indicated.
Myrothamnus flabellifolius, Table 5, was obtained from Zimbabwe and authenticated by a botanist.
Leaves of the plants were air dried and made into a powder using mortar and pestle. Ethical approval
was obtained from the University of Cape Town Human Research Ethics committee with number
HREC REF: 826/2014.
Table 5. Herbal plants and their medicinal value.
Plant Species Commonly Found African Countries Purported Medicinal Value
Newbouldia laevis Ghana, Togo, Nigeria, Congo Anti-malaria, immune booster,anti-bacterial, anti-fungal
Hyptis suaveolens Ghana, Togo, Nigeria, Congo, Benin,Guinea
Anti-bacterial, anti-fungal,
anti-malaria, anti-cholesterol
Launaea taraxacifolia Ghana, Togo, Nigeria, Congo, Benin,Guinea, Cote d’Ivoire
Anti-bacterial, anti-fungal,
anti-malaria, anti-cholesterol,
urinary infections, anti-diabetic
Boerhavia diffusa Ghana, Togo, Nigeria, Congo, Benin,Guinea, Cote d’Ivoire, South Africa
Anti-bacterial, hepatoprotective,
anti-nociceptive
Myrothamnus flabellifolious Zimbabwe, Botswana, South Africa,Uganda, Egypt Anti-viral, immune booster
4.3. Extraction of Plant Material
A sample of 10 g of leaves from each plant was prepared in 100 mL of distilled water and heated
for one hour at 60 ˝C to mimic the indigenous mode of extraction. The material was allowed to extract
for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue
reconstituted in the same volume of purified water for the extraction process to be repeated. The
supernatants were pooled and centrifuged (14,000ˆ g, 10 min) and filtered using filter paper (8 µm,
Whatman International LTD, Maidstone, UK). The filtrates were freeze-dried using a Virtis sentry
freeze dryer (the Virtis Company, NC, Gardiner, NY, USA) and the resulting powders were weighed.
The dried extracts were stored in an airtight container and stored at ´20 ˝C until needed for use.
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4.4. Screening for Inhibition
The medicinal plant extracts were screened for inhibitory effects on CYP2B6 using a two point
screening assay that used two concentrations of the extracts, 10 µg/mL and 100 µg/mL, respectively.
The assays were performed using the Vivid® CYP450 Screening Kits (Life Technologies, Grand Island,
NY, USA) with the protocol provided by the supplier. The Vivid® CYP450 screening kits are designed
to assess the metabolic activity and inhibition of the predominant human CYP450 isozymes involved
in hepatic drug metabolism by the use of 7-benzyl-oxymethyloxy-3-cyanocoumarin (BOMCC) as
a probe substrate. Briefly, the two concentrations of medicinal plants extracts mentioned above
were pre-incubated with a mixture of CYP2B6 BACULOSOME plus reagent and regeneration system
(consisting of glucose-6-phosphate and glucose-6-phosphate dehydrogenase) in Vivid® reaction buffer
I (Master pre-mix) in a black Costar 96-well plate for 20 min at 37 ˝C. The reaction was initiated by
adding a mixture of reconstituted BOMCC and NADP+ in Vivid® reaction buffer I and incubated for
30 min at 37 ˝C. The reaction was stopped by adding ice-cold 20% Tris base/80% acetonitrile (ACN).
The activity of the enzymes was monitored by measuring the formation of fluorescent metabolite
at an excitation and emission wavelength of 405/460 nm. Flourescence (SSN instruments, Set Point
Technology, South Africa) was measured using a Varian Cary eclipse advanced reads software. The
two point screening assay was followed by IC50 determination which included preparation of serial
dilutions of medicinal plant extracts from a concentration of 100 µg/mL. A mixture of CYP2B6
BACULOSOME plus reagent and regeneration system in Vivid® reaction buffer I (Master Pre-mix) in
a black costar 96-well plate were pre-incubated for 20 min at 37 ˝C. The reaction was carried out in
a similar manner to the two-point screening assay.
4.5. Time-Dependent Inhibition (TDI) Assessment Using the IC50 Curve-Shift
Determination of time-dependent inhibition (TDI) followed the same procedure as that of the
IC50 determination with slight modifications. Medicinal plant extracts with a starting concentration
of 100 µg/mL were serially diluted in duplicate six consecutive times in the black costar 96-well
plate. The black Costar 96-well plate was divided into two halves; reaction mixture A (CYP2B6
BACULOSOME, regeneration system, NADP+ and Vivid® reaction buffer I) was applied to the first
half and reaction mixture B (CYP2B6 BACULOSOME, regeneration system and Vivid® reaction buffer
I) was added into the second half of the plate. The mixture was pre-incubated at 37 ˝C for 30 min.
After pre-incubation, reconstituted BOMCC and NADP+ in Vivid® reaction buffer I was added to each
well to start the reaction. The mixture was incubated for an additional 30 min and the reaction was
terminated by adding ice-cold 20% Tris base/80% ACN. The activity of the enzymes was monitored
by measuring the formation of fluorescent metabolite at the same excitation and emission wavelength
as in the IC50 determination. For single point NADPH screening, based on the shift in the IC50 curve,
50 µg/mL concentrations of the extracts were pre-incubated with or without NADPH for 30 min. The
procedure for TDI by IC50 curve-shift was followed as explained above. This single point NADPH
screening is carried out in order to assess the significance of the effect of pre-incubating with NADPH at
a single concentration.
4.6. Relative Quantification of Selected Phenolic Compounds Using UPLC-MS
In order to identify and quantify constituents in the medicinal plant extracts, chromatographic
separation was performed on a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA)
coupled to a PDA detector and Synapt G2 (ESI negative) following the procedure described by Farag
and Wessjohann [55]. Quantification of glycosylated derivatives of epicatechin, catechin, chlorogenic
acid, caffeic acid and p-coumaric acid was calculated from calibration curves of epicatechin, catechin,
chlorogenic acid, and caffeic acid and p-coumaric acid standards, respectively. Calibration curves for
each reference compound ranged from 0.1 to 100 µg/mL.
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4.7. Data Analysis
4.7.1. IC50 Determination
The data generated was exported into an excel spreadsheet and the amount of metabolite formed
at the various concentrations relative to the control (residual activity) was calculated using Equation (1)
% Residual Activity “ pTest´Test blankq{pControl´Control blankqˆ 100 (1)
The percentage residual activity was plotted against the log transformed concentrations of the
medicinal plant extracts and the miconazole (positive CYP2B6 inhibitor). A sigmoid curve was then
fitted using non-linear regression analysis and the IC50 value was calculated using GraphPad Prism
version 5.0 (GraphPad Software Inc., San Diego, CA, USA). IC50 values were calculated with the
remaining enzyme activity and inhibitor concentration using Equation (2)
Y “ 100´rp100ˆrIsHq{pIC50H ` rIsHqs (2)
Y: remaining CYP2B6 activity (percentage of control), [I]: concentration of medicinal plant extract,
H: Hill coefficient.
4.7.2. IC50 Curve-Shift for TDI Prediction, Point Screening and Relative Quantification of
Phenolic Compound
The difference between the calculated IC50 values for pre-incubation with or without NADPH
for each medicinal plant extract and diagnostic inhibitor was compared [56]. A ratio of IC50 value
for pre-incubation without NADPH (´IC50) and pre-incubation with IC50 with NADPH (+IC50) was
then calculated to establish the fold-shift (´IC50/+IC50). Medicinal plant extracts that showed an
IC50 fold-shift of ě1.5 were thus classified as TDI and those below classified as non-TDI based on
the recommendation of Berry and Zhang [39]. For single point NADPH inhibition screening, a bar
graph was plotted showing the percentage residual activity with the concentration of extracts with or
without NADPH. The percent remaining activity was compared using the unpaired t-test with p < 0.05
considered significant. Relative quantification of metabolite profiles after UPLC-MS was performed
using XCMS data analysis software.
4.7.3. Prediction of in Vivo Herb-Drug Interaction for IC50
The assumptions to risk rank the HDI potential of all extracts used in this study was done
according to the method of Awortwe et al. [57]. Percentage yield of each extract was calculated from
amounts extracted from each herbal plant material. To predict the likelihood of medicinal plant
extracts interacting with hepatic CYP2B6, two assumptions were made: firstly, that extracts were
completely soluble in the human Gastro intestinal tract (GIT) fluid volume of 250 mL. The commonly
used dose of the various extracts was estimated to be 200–400 mg. Based on the recommended dose
used in humans, an estimated concentration per dose in GIT depending on the % yield was calculated;
Secondly, that adequate amount of each extract enters the hepatic portal vein to interact with CYP2B6,
if the IC50 values were lower than the estimated amount in the GIT.
5. Conclusions
We have shown that some of the medicinal plant extracts that have been used traditionally to
cure different diseases may need to be carefully considered in the era of HAART treatment, especially
when considering regimens containing EFV and NVP because of the effects of these herbal treatments
on CYP2B6, an enzyme that is necessary in the deposition of many therapeutically used drugs.
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